CME: Expert Perspectives and Best Practice Recommendations for Therapeutic Sequencing in NSCLC Without a Driver Mutation

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Perspectives & Best Practice Recommendations for Therapeutic Sequencing in NSCLC Without a Driver Mutation

Program Information
Expert Perspectives & Best Practice Recommendations for Therapeutic Sequencing in NSCLC Without a Driver Mutation
What factors influence therapeutic sequencing, and how may they affect second-line treatment options for your NSCLC patients?

Available credits: 0.25

Time to complete: 15 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    In this 15-minute accredited CME audiocast, Dr. Tsao presents 2 cases of patients with advanced NSCLC without a driver mutation and discusses how to manage these patients after first-line treatment. The first case is a patient who progresses on platinum-based chemotherapy, and the second case is a patient who progresses on pembrolizumab-pemetrexed-carboplatin. 

  • Faculty

    Anne S. Tsao, MD
    Professor, Department of Thoracic/Head and Neck Medical Oncology
    Division of Cancer Medicine
    Director, Mesothelioma Program
    Director, Thoracic Chemo-Radiation Program
    University of Texas MD Anderson Cancer Center
    Houston, TX

  • Activity Planners

    Christie Avraamides, PhD
    Clinical Content Manager
    Baltimore, MD

    Samantha Gordon
    CME Specialist
    Baltimore, MD

    Kathryn Schaefer, MSN, RN, CPHRM
    Senior Manager, Accreditation and Compliance
    East Lansing, MI

  • Learning Objective

    Upon completion, participants should be able to:

    • Develop individualized treatment plans for patients with metastatic NSCLC without driver mutations in the second-line setting


  • Target Audience

    This activity is intended for oncologists.

  • Statement of Need

    The availability of new first-line treatment options for metastatic non–small cell lung cancer (NSCLC) in patients without an actionable mutation allows for greater treatment individualization and improved outcomes. However, oncologists are now challenged to optimally sequence therapies in the second-line setting because there are no randomized trials to guide therapeutic decisions. Furthermore, evidence suggests that the selection of second-line agents in metastatic NSCLC without an actionable mutation may not be consistent with guideline recommendations. Therefore, oncologists need education and guidance on the factors that influence therapeutic sequencing and on second-line treatment options. 

  • Provider

  • Accreditation/Designation Statements

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Instructions to Receive Credit

    To receive credit, read the introductory CME material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

  • Disclosure Policy

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

  • Disclosure Statements

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Anne S. Tsao, MD

    Consulting fees/advisory boards: AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Inc., F. Hoffman-La Roche Ltd., Genentech, Huron, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Seattle Genetics, Takeda Pharmaceuticals North America, Inc.
    Contracted research: Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Epizyme, Genentech, Merck & Co., Inc., Millennium: The Takeda Oncology Company, Polaris Pharmaceuticals, Seattle Genetics

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Statement of Evidence-based Content

    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

  • Contact Information

    For CME-related questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • ADA Statement

    Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Privacy & Confidentiality

    Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

  • Acknowledgement of Commercial Support

    This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit

LIVE ON REACHMD RADIOBack to live radio


Programs 11/13/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.